MoonLake Immunotherapeutics (MLTX) Non-Current Debt (2025 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Non-Current Debt of $99.0 million for Q1 2026, up 35.6% year-over-year from $73.0 million in Q1 2025, and up 33.63% quarter-over-quarter from $74.1 million in Q4 2025.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Non-Current Debt (2025 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $99.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 35.6% year-over-year to $99.0 million; the TTM figure through Mar 2026 stood at $99.0 million (up 35.6% YoY), while the FY2025 annual figure was $74.1 million, changed N/A from the prior year.
- Non-Current Debt for Q1 2026 stood at $99.0 million, up from $74.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $99.0 million in Q1 2026, with the low at $73.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 10 | MoonLake Immunotherapeutics | 1.11 Bn | 570.96 Mn | - | 99.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.51 Mn |
| Mar 31, 2026 | 99.02 Mn |
| Dec 31, 2025 | 74.10 Mn |
| Sep 30, 2025 | 73.74 Mn |
| Jun 30, 2025 | 73.40 Mn |
| Mar 31, 2025 | 73.02 Mn |